Peapod Lane Capital LLC Takes Position in Chimerix, Inc. (NASDAQ:CMRX)

Peapod Lane Capital LLC bought a new position in shares of Chimerix, Inc. (NASDAQ:CMRX) in the 4th quarter, Holdings Channel.com reports. The fund bought 754,566 shares of the biopharmaceutical company’s stock, valued at approximately $2,626,000. Chimerix accounts for approximately 2.6% of Peapod Lane Capital LLC’s investment portfolio, making the stock its 11th largest position.

Several other large investors also recently bought and sold shares of CMRX. Valeo Financial Advisors LLC grew its holdings in Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 69,505 shares in the last quarter. Stoneridge Investment Partners LLC grew its stake in shares of Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 8,134 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in Chimerix by 154.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after buying an additional 496,823 shares during the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Stock Performance

Shares of NASDAQ:CMRX opened at $4.44 on Thursday. Chimerix, Inc. has a 52 week low of $0.75 and a 52 week high of $4.48. The company has a 50-day moving average price of $3.38 and a 200 day moving average price of $1.77.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wedbush restated an “outperform” rating and issued a $6.00 target price on shares of Chimerix in a report on Tuesday, December 10th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Chimerix in a research report on Monday, December 30th.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.